20.08.2024:
Following treatment for rapidly progressing metastatic castration-resistant prostate cancer with ¹⁷⁷Lu-PSMA radioligand therapy under Norway's compassionate use programme, significant reduction of the metastases was observed on PET/CT. The therapeutic effect was transient. A man in his seventies...